Pathstone Family Office’s Idexx Laboratories IDXX Stock Holding History

Pathstone Family Office’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$4.81M	Buy	11,001 +3,656	+50%	+$1.82M	0.04%	277
2023 Q2	$3.68M	Buy	7,345 +913	+14%	+$438K	0.05%	210
2023 Q1	$3.25M	Sell	6,432 -12,092	-65%	-$5.79M	0.05%	207
2022 Q4	$6.76M	Buy	18,524 +2,833	+18%	+$1.1M	0.06%	232
2022 Q3	$5.11M	Buy	15,691 +11,794	+303%	+$4.33M	0.05%	230
2022 Q2	$1.37M	Buy	3,897 +1,420	+57%	+$579K	0.03%	278
2022 Q1	$1.35M	Sell	2,477 -215	-8%	-$113K	0.03%	253
2021 Q4	$1.77M	Buy	2,692 +202	+8%	+$127K	0.04%	212
2021 Q3	$1.55M	Sell	2,490 -6	-0.2%	-$4.03K	0.05%	204
2021 Q2	$1.58M	Sell	2,496 -51	-2%	-$28.2K	0.05%	185
2021 Q1	$1.25M	Buy	2,547 +2,453	+2,610%	+$1.23M	0.04%	180
2020 Q4	$47K	Buy	+94	New	+$42.1K	﹤0.01%	526
2019 Q2	–	Sell	-8	Closed	-$2K	–	757
2019 Q1	$2K	Buy	+8	New	+$1.65K	﹤0.01%	771

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Pathstone Family Office's IDXX Position: Q3 2023 in Review

Pathstone Family Office increased its Idexx Laboratories (IDXX) stake by 50% in Q3 2023, buying an estimated $1.82M and bringing the position to 11,001 shares worth $4.81M. The position accounts for 0.04% of the portfolio, ranked #277.

Pathstone Family Office first reported a position in IDXX in Q1 2019 and has held it in 13 quarters since. The position peaked at $6.76M in Q4 2022. 1,059 funds tracked by Wall St. Rank hold IDXX as of Q3 2023.

Pathstone Family Office held 11,001 shares of Idexx Laboratories worth $4.81M as of Q3 2023.
Pathstone Family Office bought 3,656 Idexx Laboratories shares in Q3 2023, an estimated $1.82M.
Idexx Laboratories made up 0.04% of Pathstone Family Office's portfolio in Q3 2023, its #277 holding.
Pathstone Family Office first reported a position in Idexx Laboratories in Q1 2019 and has held it in 13 quarters since.
Pathstone Family Office's Idexx Laboratories position peaked at $6.76M in Q4 2022.
1,059 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.